Hui Zhu

5.0k total citations · 1 hit paper
152 papers, 3.7k citations indexed

About

Hui Zhu is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Hui Zhu has authored 152 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 87 papers in Oncology, 81 papers in Pulmonary and Respiratory Medicine and 34 papers in Molecular Biology. Recurrent topics in Hui Zhu's work include Lung Cancer Research Studies (47 papers), Lung Cancer Treatments and Mutations (46 papers) and Lung Cancer Diagnosis and Treatment (28 papers). Hui Zhu is often cited by papers focused on Lung Cancer Research Studies (47 papers), Lung Cancer Treatments and Mutations (46 papers) and Lung Cancer Diagnosis and Treatment (28 papers). Hui Zhu collaborates with scholars based in China, United States and United Kingdom. Hui Zhu's co-authors include Li Kong, Jinming Yu, Hua Jane Lou, Fang Shi, Anqin Han, Jinming Yu, Yinping Dong, Yang Liu, Xiaoyang Zhai and Wenxiao Jia and has published in prestigious journals such as Nucleic Acids Research, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Hui Zhu

143 papers receiving 3.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Abscopal effect of radiotherapy combined with immune checkpoint inhibitors

2018 340 citations Li Kong, Hui Zhu et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Hui Zhu China	31	1.7k	1.1k	957	580	550	152	3.7k
Wouter B. Nagengast Netherlands	27	1.2k 0.7×	890 0.8×	787 0.8×	816 1.4×	752 1.4×	91	3.4k
Daniel M. Aebersold Switzerland	34	1.2k 0.7×	1.4k 1.2×	1.4k 1.5×	625 1.1×	316 0.6×	225	4.6k
Peter Bronsert Germany	31	1.7k 1.0×	1.2k 1.1×	1.4k 1.5×	401 0.7×	231 0.4×	142	3.9k
Alicia Tosoni Italy	29	771 0.5×	1.3k 1.2×	1.1k 1.2×	799 1.4×	281 0.5×	103	4.2k
Alexander Quaas Germany	36	2.1k 1.3×	1.2k 1.1×	1.1k 1.2×	406 0.7×	266 0.5×	227	4.8k
Emmanouil Fokas Germany	40	2.6k 1.6×	1.1k 1.0×	1.7k 1.8×	447 0.8×	262 0.5×	154	5.1k
Miguel Á. Idoate Spain	28	1.1k 0.6×	690 0.6×	809 0.8×	193 0.3×	361 0.7×	146	3.2k
Toru Mukohara Japan	28	2.3k 1.4×	1.7k 1.5×	1.7k 1.8×	448 0.8×	436 0.8×	128	4.1k
Jason Chia‐Hsien Cheng Taiwan	37	1.0k 0.6×	1.4k 1.3×	859 0.9×	771 1.3×	250 0.5×	208	4.5k
Fabiana Tatangelo Italy	37	1.7k 1.0×	534 0.5×	653 0.7×	956 1.6×	198 0.4×	129	3.2k

Countries citing papers authored by Hui Zhu

Since Specialization

Citations

This map shows the geographic impact of Hui Zhu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hui Zhu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hui Zhu more than expected).

Fields of papers citing papers by Hui Zhu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hui Zhu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hui Zhu. The network helps show where Hui Zhu may publish in the future.

Co-authorship network of co-authors of Hui Zhu

This figure shows the co-authorship network connecting the top 25 collaborators of Hui Zhu. A scholar is included among the top collaborators of Hui Zhu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hui Zhu. Hui Zhu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wang, Gaonan, Hui Zhu, Xiaodong Shi, et al.. (2025). DNA-Compatible Huisgen [3 + 2] Cycloaddition of In Situ Formed Nitrile Oxides with Alkenes or Alkynes to Synthesize Isoxazolines or Isoxazoles. The Journal of Organic Chemistry. 90(16). 5460–5468. 3 indexed citations

Fang, Wen‐Feng, Haijun Zhao, Yuanyuan Zhao, et al.. (2025). OA10.03 Phase I/II Study of Iza-Bren (BL-B01D1) as Monotherapy in Patients With Locally Advanced or Metastatic EGFR Mutated NSCLC. Journal of Thoracic Oncology. 20(10). S31–S32.

Zhou, Fei, Hui Zhu, Ying Nie, et al.. (2025). Epigallocatechin Gallate Inhibits Cell Proliferation Promoted by TNFα/IL1β‐NFκB‐PLAU Inflammatory Signaling in Esophageal Squamous Cell Carcinoma. Journal of Food Biochemistry. 2025(1).

Guo, Hongbo, et al.. (2024). Roles of naïve CD4+ T cells and their differentiated subtypes in lung adenocarcinoma and underlying potential regulatory pathways. Journal of Translational Medicine. 22(1). 781–781. 2 indexed citations

Wang, Lin, Bingwen Zou, Haiyu Zhou, et al.. (2024). Chemoradiotherapy (CRT) Combined with Consolidative Iruplinalkib for ALK/ROS1+ Unresectable Non-Small Cell Lung Cancer (NSCLC): ALK+ Cohort Results from Part 1 of the INNOVATION Study. International Journal of Radiation Oncology*Biology*Physics. 120(2). e76–e77.

Tian, Yaru, et al.. (2024). Strong PD-L1 affect clinical outcomes in advanced NSCLC treated with third-generation EGFR-TKIs. Future Oncology. 20(32). 2481–2490. 2 indexed citations

Zhou, Kun, et al.. (2024). High-intensity focused ultrasound (HIFU) assisted by a rectal Foley catheter for the treatment of recurrent mucinous ovarian cancer: a case report and literature review. Frontiers in Oncology. 14. 1498631–1498631.

Jia, Wenxiao, Hongbo Guo, Min Wang, et al.. (2023). High post‐chemotherapy TIL and increased CD4+TIL are independent prognostic factors of surgically resected NSCLC following neoadjuvant chemotherapy. SHILAP Revista de lepidopterología. 4(1). e213–e213. 8 indexed citations

Zhang, Xiao, Xiao Liu, Jiuzhou Zhao, et al.. (2023). First report of furmonertinib as a first-line treatment in advanced lung adenocarcinoma patients harboring EGFR exon 20 insertion mutations after the kinase domain αC-helix: Two case reports and a literature review. Medicine. 102(52). e36667–e36667. 2 indexed citations

10.

Zhang, Xiao, Huan Han, Jiuzhou Zhao, et al.. (2022). Case Report: A good response to furmonertinib second-line treatment of an advanced lung adenocarcinoma patient with a rare EGFR exon 20 N771_P772insH mutation: A case report and literature review. Frontiers in Pharmacology. 13. 964606–964606. 4 indexed citations

11.

Zhai, Xiaoyang, Wanhu Li, Ji Li, et al.. (2021). Therapeutic effect of osimertinib plus cranial radiotherapy compared to osimertinib alone in NSCLC patients with EGFR-activating mutations and brain metastases: a retrospective study. Radiation Oncology. 16(1). 233–233. 19 indexed citations

12.

Zhang, Qi, et al.. (2019). Effect evaluation of six-character exercise breathing assisted long-term home oxygen therapy in patients with chronic obstructive pulmonary disease. The Journal of practical nursing. 35(27). 2108–2113. 3 indexed citations

13.

Li, Ji, Li Zhang, Hui Zhu, et al.. (2018). Leukocyte Telomere Length and Clinical Outcomes of Advanced Lung Adenocarcinoma Patients with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Treatment. DNA and Cell Biology. 37(11). 903–908. 3 indexed citations

14.

Shen, Wenbin, Hongmei Gao, Shuchai Zhu, et al.. (2016). The dose study of radiation gastritis caused by esophageal cancer radical postoperative prophylactic irradiation. Zhonghua fangshe zhongliuxue zazhi. 25(8). 818–822. 1 indexed citations

15.

Teng, Feifei, Xiangjiao Meng, Li Kong, et al.. (2015). Tumor-infiltrating lymphocytes, forkhead box P3, programmed death ligand-1, and cytotoxic T lymphocyte–associated antigen-4 expressions before and after neoadjuvant chemoradiation in rectal cancer. Translational research. 166(6). 721–732.e1. 105 indexed citations

16.

Sun, Juan, et al.. (2012). Synthesis, molecular modeling and biological evaluation of 2-aminomethyl-5-(quinolin-2-yl)-1,3,4-oxadiazole-2(3H)-thione quinolone derivatives as novel anticancer agent. European Journal of Medicinal Chemistry. 60. 23–28. 97 indexed citations

17.

Li, Ling, Man Hu, Hui Zhu, et al.. (2010). Comparison of 18F-Fluoroerythronitroimidazole and 18F-Fluorodeoxyglucose Positron Emission Tomography and Prognostic Value in Locally Advanced Non–Small-Cell Lung Cancer. Clinical Lung Cancer. 11(5). 335–340. 46 indexed citations

18.

Wang, Huiwen, et al.. (2010). Promotion of exon 6 inclusion in HuD pre-mRNA by Hu protein family members. Nucleic Acids Research. 38(11). 3760–3770. 41 indexed citations

19.

Zhu, Hui, et al.. (2009). The neurofibromatosis type I pre-mRNA is a novel target of CELF protein-mediated splicing regulation. Nucleic Acids Research. 38(1). 253–264. 29 indexed citations

20.

Zhang, Baijiang, Hui Li, Hui Zhu, et al.. (2007). Potential role of 18 FDG PET-CT for target volume definition of metastatic lymph nodes in advanced esophageal carcinoma. Zhonghua fangshe zhongliuxue zazhi. 16(1). 10–14. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact